Marker Therapeutics, Inc. MRKR
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -40.08%
- 1 year
- +1.45%
- Market cap
- 14.89M
- Revenue (ttm)
- 3.73M
- Profit margin
- -278.22%
- EPS (ttm)
- -0.42
- Shares out
- 8.92M
- Forward P/E
- -2.34
- YTD return
- -40.08%
- 1-year return
- +1.45%
- Volume
- 50.36K
- Avg volume
- 113.94K
- Open
- 0.8955
- Previous close
- 0.8965
- Day's range
- 0.8928 – 0.9544
- 52-week range
- 0.86 – 2.19
- Beta
- 1.49
- Analysts
- Strong Buy
- Price target
- 19.00 (+2028.1%)
- Earnings date
- Mar 27, 2024
5D -0.0661 (-6.89%)
Key statistics
- Enterprise value
- 19.59M
- PEG ratio
- 0.00
- Price / sales
- 8.19
- Price / book
- 2.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 53.30%
- Free cash flow
- -7.40M
- Total cash
- 7.80M
- Total debt
- 0
- Return on equity
- -71.74%
- Short % of float
- 1.09%
- 50-day average
- 3.71
- 200-day average
- 3.97
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 27, 2024
Expected Mar 27, 2024. Consensus EPS estimate -0.28.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.26 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.25 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.27 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.34 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.47 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 30, 2024 | Ladenburg Thalmann | init | — | Buy |
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- markertherapeutics.com
News
Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer 
12 Health Care Stocks Moving In Friday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's After-Market Session - 12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why Motorcar Parts of America Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Stocks That Hit 52-Week Lows On Friday 
Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on MRKR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 12.01% | 1,071,428 | 3.66M | Sep 29, 2024 |
| Aisling Capital Management LP | 3.52% | 314,286 | 1.07M | Sep 29, 2024 |
| Vanguard Group Inc | 2.72% | 243,122 | 831.48K | Sep 29, 2024 |
| AR Asset Management, Inc. | 0.83% | 73,700 | 252.05K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.80% | 71,561 | 244.74K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.45% | 39,750 | 135.94K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.72% | 153,473 | 524.88K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.98% | 87,137 | 298.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 39,946 | 136.62K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.19% | 16,579 | 56.70K | Oct 30, 2024 |
| DFA U.S. Small Cap Series | 0.18% | 15,900 | 54.38K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 12,811 | 43.81K | Oct 30, 2024 |